LIFECORE BIOMEDICAL, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LIFECORE BIOMEDICAL, INC. (LFCR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.08M.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.70M.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.39M.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-05-25 was $1.81M, a 13.15% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.16M, a 63.08% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.23M, a 72.45% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.61M, a 38.50% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.61M, a 22.38% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 7 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-05 | $3.78M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $5.67M 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $2.39M 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $1.81M 10-Q · filed 2026-08-05 | $4.37M 10-Q · filed 2026-08-05 | $7.74M derived: sum of 3 quarters · filed 2026-08-05 | $10.16M 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $2.55M 10-Q · filed 2026-05-06 | $5.92M derived: sum of 2 quarters · filed 2026-05-06 | $8.34M 10-Q · filed 2025-04-03 | $9.95M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-11-24 | $3.37M 10-Q · filed 2025-01-02 | $5.79M derived: sum of 2 quarters · filed 2025-11-06 | $7.39M derived: sum of 3 quarters · filed 2026-03-16 | $8.89M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-08-25 | $2.42M 10-Q · filed 2025-11-06 | $4.02M derived: sum of 2 quarters · filed 2026-03-16 | $5.52M derived: sum of 3 quarters · filed 2026-03-16 | $7.11M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-05-26 | $1.60M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $3.10M derived: sum of 2 quarters · filed 2026-03-16 | $4.69M derived: sum of 3 quarters · filed 2026-03-16 | $6.23M 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $1.50M 10-Q · filed 2025-04-03 | $3.08M derived: sum of 2 quarters · filed 2025-04-03 | $4.63M 10-Q · filed 2025-04-03 | ||
| 2023-11-26 | $1.58M 10-Q · filed 2025-01-02 | $3.13M derived: sum of 2 quarters · filed 2025-01-02 | |||
| 2023-08-27 | $1.54M 10-Q · filed 2025-01-02 | ||||
| 2023-05-28 | $3.61M 10-K · filed 2024-08-26 | ||||
| 2023-02-26 | $903.00K 10-Q · filed 2024-08-09 | $2.01M derived: sum of 2 quarters · filed 2024-08-09 | $2.80M derived: sum of 3 quarters · filed 2024-08-09 | ||
| 2022-11-27 | $1.11M 10-Q · filed 2024-08-09 | $1.89M derived: sum of 2 quarters · filed 2024-08-09 | |||
| 2022-08-28 | $785.00K 10-Q · filed 2024-08-09 | ||||
| 2022-05-29 | $2.61M 10-K · filed 2024-08-26 | ||||
| 2022-02-27 | $622.00K 10-K · filed 2024-03-20 | $1.31M derived: sum of 2 quarters · filed 2024-03-20 | $1.93M derived: sum of 3 quarters · filed 2024-03-20 | ||
| 2021-11-28 | $686.00K 10-K · filed 2024-03-20 | $1.31M derived: sum of 2 quarters · filed 2024-03-20 | |||
| 2021-08-29 | $620.00K 10-K · filed 2024-03-20 | ||||
| 2021-05-30 | $3.36M 10-K · filed 2024-03-20 | ||||
| 2021-02-28 | $797.00K 10-K · filed 2024-03-20 | $1.69M derived: sum of 2 quarters · filed 2024-03-20 | $2.58M derived: sum of 3 quarters · filed 2024-03-20 | ||
| 2020-11-29 | $895.00K 10-K · filed 2024-03-20 | $1.79M derived: sum of 2 quarters · filed 2024-03-20 | |||
| 2020-08-30 | $892.00K 10-K · filed 2024-03-20 | ||||
| 2020-05-31 | $2.42M 10-K/A · filed 2023-03-16 | ||||
| 2020-02-23 | $566.00K 10-Q · filed 2021-04-08 | $1.35M derived: sum of 2 quarters · filed 2021-04-08 | $1.88M derived: sum of 3 quarters · filed 2021-04-08 | ||
| 2019-11-24 | $787.00K 10-Q · filed 2021-04-08 | $1.31M derived: sum of 2 quarters · filed 2021-04-08 | |||
| 2019-08-25 | $528.00K 10-Q · filed 2021-04-08 | ||||
| 2019-05-26 | $3.56M 10-K · filed 2021-07-29 | ||||
| 2019-02-24 | $816.00K 10-Q · filed 2020-04-03 | $1.75M derived: sum of 2 quarters · filed 2020-04-03 | $2.48M derived: sum of 3 quarters · filed 2020-04-03 | ||
| 2018-11-25 | $938.00K 10-Q · filed 2020-04-03 | $1.67M 10-Q · filed 2019-01-07 | |||
| 2018-08-26 | $728.00K 10-Q · filed 2020-04-03 | ||||
| 2017-11-26 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-01-05 | $2.07M 10-Q · filed 2018-01-05 | |||
| 2017-08-27 | $950.00K 10-Q · filed 2017-09-28 | ||||
| 2017-02-26 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-07 | $2.84M 10-Q · filed 2017-04-07 | |||
| 2016-11-27 | $1.77M 10-Q · filed 2017-01-05 | ||||
| 2016-02-28 | $884.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $1.78M derived: sum of 2 quarters · filed 2016-03-30 | $2.58M 10-Q · filed 2016-03-30 | ||
| 2015-11-29 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $1.70M 10-Q · filed 2016-01-07 | |||
| 2015-08-30 | $797.00K 10-Q · filed 2015-10-01 | ||||
| 2015-03-01 | $391.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-02 | $741.00K derived: sum of 2 quarters · filed 2015-04-02 | $1.14M 10-Q · filed 2015-04-02 | ||
| 2014-11-30 | $350.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-09 | $748.00K 10-Q · filed 2015-01-09 | |||
| 2014-08-31 | $398.00K 10-Q · filed 2014-10-08 | ||||
| 2014-02-23 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-28 | $714.00K derived: sum of 2 quarters · filed 2014-03-28 | $992.00K 10-Q · filed 2014-03-28 | ||
| 2013-11-24 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-01-03 | $639.00K 10-Q · filed 2014-01-03 | |||
| 2013-08-25 | $278.00K 10-Q · filed 2013-09-26 | ||||
| 2013-02-24 | $464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-04-04 | $787.00K derived: sum of 2 quarters · filed 2013-04-04 | $1.14M 10-Q · filed 2013-04-04 | ||
| 2012-11-25 | $323.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-01-04 | $671.00K 10-Q · filed 2013-01-04 | |||
| 2012-08-26 | $348.00K 10-Q/A · filed 2013-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |